Trial reportHuman vaccines & immunotherapeutics2026
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
Trial report in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05815498 (A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283 Compared With mRNA-1273 in Participants Aged ≥12 Years for the Prevention of COVID-19), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283 Compared With mRNA-1273 in Participants Aged ≥12 Years for the Prevention of COVID-19
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 neutralizing antibodies (nAbs) are strongly inversely associated with COVID-19 risk and have correlated with vaccine efficacy across multiple clinical trials conducted during the COVID-19 pandemic. As SARS-CoV-2 continues to evolve in the endemic era, it is important to determine whether nAb levels remain a valid statistical correlate of protection and potential surrogate endpoints for emerging variants. The next-generation COVID-19 vaccine, mRNA-1283, has recently received regulatory approval worldwide. In the Phase 3 NextCOVE trial (NCT05815498), which enrolled more than 10,000 participants aged ≥12 y, mRNA-1283 (10 µg; bivalent ancestral plus Omicron BA.4/BA.5) met the non-inferiority criterion for relative vaccine efficacy (rVE) versus mRNA-1273 (50 µg; bivalent) and elicited higher nAb responses. In this correlate analysis of the NextCOVE trial, we evaluated Day 29 nAbs against ancestral D614G, BA.4/BA.5, and XBB.1.5 variants as correlates of risk (CoRs) and correlates of protection (CoPs) for COVID-19 after vaccination with mRNA-1283 or mRNA-1273. Across multiple statistical frameworks, higher Day 29 nAb levels were consistently associated with lower COVID-19 risk and higher estimated rVE. The estimated hazard ratios per 10-fold increase in Day 29 nAbs against D614G, BA.4/BA.5, and XBB.1.5 were 0.70 (95% confidence interval [CI]: 0.48-1.02;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.